Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (s...
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C r...
PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Al...
BeiGene, a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an ...
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of...
Sibel Health announces two additional FDA-clearances enabling its advanced wearable sensors to operate with compatible third party software applications. I...
Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy(ipilimumab) compared to in...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today th...
Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, today announced a reorganization to best support the company as...
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) fo...
Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE mark in Eu...
Hypoparathyroidism is a rare endocrine disease with multi-organ impacts affecting an estimated 70,000 to 90,000 people in the United States Ascendi...
U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those th...
Novartis is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a ground...
© 2025 Biopharma Boardroom. All Rights Reserved.
